CurrentCapital BluecrossPolicy MP 2.257

Genetic Testing for Duchenne and Becker Muscular Dystrophy

This policy governs when genetic testing of the DMD gene is considered medically necessary or investigational for individuals (including male probands, at-risk female relatives, and at-risk male offspring) for diagnosis, surveillance, and reproductive risk assessment.

Policy Summary

PayerCapital Bluecross

PolicyGenetic Testing for Duchenne and Becker Muscular Dystrophy

Policy CodePolicy MP 2.257

Change TypeNo material change

Effective DateNov 1, 2025

Next Review DateSep 23, 2025

Key ActionOrder DMD gene testing only for specified medically necessary indications (diagnostic testing in symptomatic males, targeted familial variant testing for at-risk relatives, or testing at-risk male offspring).

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

4.8/100kDMD prevalence

1.6/100kBMD prevalence

~1/3de novo proportion

4 codesCovered CPTs

2023

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

Medically Necessary Indications

Genetic testing for DMD gene variants is covered when any of the following specific situations apply:

Covered indications (any): 1) In an individual assigned male at birth with signs and symptoms of a dystrophinopathy in order to confirm the diagnosis and direct treatment; 2) For at-risk relatives assigned female at birth to confirm or exclude the need for cardiac surveillance or for preconception testing to determine the likelihood of an affected offspring in an individual considering pregnancy; 3) For at-risk offspring assigned male at birth to confirm or exclude the need for medical and cardiac surveillance.

See Policy Guidelines for definitions of at-risk AFB and AMB.

Investigational

Testing considered investigational:

Investigational indications: Genetic testing for DMD gene variants is investigational in all other situations not specified as medically necessary due to insufficient evidence of benefit.

Supported testing indications

Covered when testing meets clinical purposes described below:

Diagnostic testing in symptomatic males: Genetic testing of the DMD gene to confirm diagnosis without muscle biopsy is supported because virtually all males with DMD or BMD have identifiable DMD disease-associated variants and testing has high clinical sensitivity; results can direct treatment and obviate the need for biopsy.

Evidence sufficient for meaningful improvement in net health outcome (see Summary of Evidence).

Targeted familial variant testing in female relatives: Targeted DMD testing for a known familial variant to determine carrier status is supported; determination of carrier status necessitates or eliminates the need for routine cardiac surveillance and can inform reproductive decision making.

Direct clinical utility evidence is limited but chain of evidence is strong (see Summary of Evidence).

Targeted familial variant testing in asymptomatic male relatives: Targeted testing of an asymptomatic male offspring of a female carrier or an asymptomatic male sibling for a known familial DMD variant is supported to determine need for increased medical or cardiac surveillance.

Any clinical indication for genetic testing of the DMD gene that is not explicitly listed in the policys medically necessary criteria is considered investigational. The policy specifies coverage only for: (1) diagnostic testing in an individual assigned male at birth with signs or symptoms of a dystrophinopathy to confirm diagnosis and direct treatment; (2) targeted testing of at-risk relatives assigned female at birth for carrier status to guide cardiac surveillance and reproductive decision making; and (3) targeted testing of at-risk male offspring to determine need for medical and cardiac surveillance. Outside these specified situations, evidence is insufficient to support clinical benefit and testing is not covered.

The policy does not list a separate set of explicit procedural exclusions; instead, coverage is determined by whether a requested test meets the policys medical necessity criteria and by the members benefit. The Coding sections note clarifies that identification of a code in the policy does not, by itself, guarantee coverage and that claims may be denied if a service is not medically necessary or not covered under the members benefit.

Covered Indications and Use Cases

Diagnosis confirmation in symptomatic AMB proband; testing of at-risk AFB relatives for cardiac surveillance or preconception risk assessment; testing of at-risk AMB offspring for medical and cardiac surveillance.

Primary covered scenario: Genetic testing to confirm diagnosis in an individual assigned male at birth with signs and symptoms of a dystrophinopathy, eliminating the need for muscle biopsy and guiding treatment and follow-up.

High clinical sensitivity; see Summary of Evidence (chunk 23).

AFB relatives - cardiac and reproductive: Targeted or diagnostic testing in at-risk relatives assigned female at birth to determine carrier status and confirm or exclude the need for routine cardiac surveillance or for preconception risk assessment when pregnancy is being considered.

Definitions of at-risk AFB and recommended surveillance are in Policy Guidelines (chunk 2).

Coding

Covered when medically necessaryCPTCovered

81161
81403
81408
0218U

Relevant ICD-10 CodesICD-10

G71.01	Duchenne or Becker muscular dystrophy.
R62.59	Other lack of expected normal physiological development in childhood.
Z31.430	Encounter of female for testing for genetic disease carrier status for procreative management.
Z84.81	Family history of carrier of genetic disease.
Z84.89	Family history of other specified conditions

inv-08: Serum creatine kinase elevation

Typical CK elevation for DMDSerum creatine kinase (CK) elevation is at least 10–20 times normal (approximately 5,000 IU/L to 150,000 IU/L)

Clinical contextCK elevation is nonspecific but is always present in affected DMD patients and often prompts further evaluation (e.g., genetic testing)

Triggers for testingMarked CK elevation detected incidentally or during evaluation of abnormal muscle function in a male child should prompt consideration of DMD testing

inv-09: CK elevation in BMD

Typical CK elevation for BMDSerum creatine kinase (CK) shows moderate-to-severe elevation of about 5–100 times the normal level

Clinical course

Eligibility Requirements

Coverage for testing of at-risk relatives depends on the familial relationship to a proband or a known familial DMD variant. The policy specifies targeted testing for first- and second-degree relatives as described in the Policy Guidelines and supports testing of at-risk female relatives to determine carrier status (impacting cardiac surveillance and reproductive planning) and testing of asymptomatic male offspring or male siblings to determine need for increased medical and cardiac surveillance.

Supplemental eligibility considerations include whether the requested test is a targeted familial variant assay versus broader diagnostic DMD gene testing, and whether prior testing in the family has identified a known pathogenic variant. Targeted testing for a known familial variant is expected to have high clinical validity and is supported when it directly informs surveillance or reproductive decisions.

Clinical eligibility should be documented with findings consistent with a dystrophinopathy when testing a symptomatic individual (for example, markedly elevated serum creatine kinase, gait disturbance, or a positive Gower sign). Molecular testing (deletion/duplication analysis and sequencing) can often establish diagnosis without the need for muscle biopsy; biopsy is reserved when molecular testing is non-diagnostic.

When testing at-risk relatives, documentation should indicate the familial pathogenic variant or a clear family history (ICD-10 family-history codes may be applicable). For asymptomatic male relatives of a known carrier, testing is intended to determine the need for increased medical and cardiac surveillance rather than routine population screening.

Provider Actions and Documentation

Prior Authorization

Product-specific Authorization Requirements

This policy is applicable only to certain Capital Blue Cross programs and products; refer to member benefit documents for coverage details and to alternate manuals (for example, the FEP Medical Policy Manual) when noted. Providers should confirm product-specific authorization requirements before ordering testing.

Policy applies to certain Capital Blue Cross programs and products; refer to member benefit variations and alternate manuals (e.g., FEP Medical Policy Manual).

Billing Rule

Coding Identification and Coverage Determination

Listing a code in the coding section is informational only and does not guarantee coverage. Coverage for services is determined by the member's benefit plan and whether the service is medically necessary. Prior authorization may be required depending on the member's benefit.

Background

Dystrophinopathies include Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and DMD-associated dilated cardiomyopathy. These conditions are X-linked and caused by pathogenic variants in the DMD gene (dystrophin); molecular confirmation is achieved by identifying a pathogenic variant in DMD. DMD typically presents in early childhood with progressive muscle weakness and markedly elevated serum creatine kinase (often at least 100 to 20 times normal), whereas BMD has later onset and milder skeletal muscle involvement but an increased risk of cardiomyopathy. The DMD gene is large with a complex variant spectrum (>5000 reported disease-associated variants) and a substantial de novo variant rate.

Definitions

inv-19: Variant classification (ACMG-AMP)

ACMG-AMP standard termsStandard variant interpretation terminology: pathogenic, likely pathogenic, variant of uncertain significance (VUS), likely benign, and benign

Nomenclature guidanceHGVS nomenclature is used to report DNA variants and is recommended for clinical reporting

ApplicabilityACMG-AMP recommendations apply to clinical laboratory testing including single genes, panels, exomes, and genomes

inv-20: At-risk individuals assigned female at birth (AFB)

Definition of at-risk AFBAt-risk individuals assigned female at birth (AFB) are first- and second-degree relatives, including the proband's mother, AFB siblings, AFB offspring, the proband's maternal grandmother, maternal aunts, and their offspring

Clinical relevance

Not Covered

Genetic testing of the DMD gene for indications other than those specified as medically necessary in this policy is considered investigational and not covered. The policy rationale notes insufficient evidence of clinical utility for uses outside: confirming diagnosis in symptomatic males, targeted familial variant testing of at-risk female relatives for carrier status and cardiac surveillance, and targeted testing of at-risk male offspring to guide surveillance.

The policy extract does not enumerate specific tests or indications that are categorically excluded; however, the Coding section cautions that listing a procedure or diagnosis code in the policy does not automatically confer coverage. Coverage decisions remain subject to the members benefit terms and medical necessity determinations, and prior authorization rules may apply for codes listed as "Covered when medically necessary."

Policy Summary

PayerCapital Bluecross

PolicyGenetic Testing for Duchenne and Becker Muscular Dystrophy

Policy CodePolicy MP 2.257

Change TypeNo material change

Effective DateNov 1, 2025

Next Review DateSep 23, 2025

SourceLink

On This Page

Detection informs surveillance and downstream management (see Summary of Evidence).

AMB offspring - surveillance:

Targeted testing of at-risk offspring assigned male at birth (asymptomatic male offspring of an AFB carrier or asymptomatic male sibling of an affected individual) to determine DMD status and need for medical and cardiac surveillance.

See Policy Guidelines for definition of at-risk AMB (chunk 2) and evidence summary (chunk 24).

Male with signs and symptoms of a dystrophinopathy for diagnostic DMD gene testing to confirm diagnosis without muscle biopsy.

Diagnostic testing in symptomatic male: Individual assigned male at birth with clinical signs or symptoms of a dystrophinopathy who receives genetic testing of the DMD gene to confirm diagnosis without muscle biopsy; testing expected to identify disease-associated DMD variants given high clinical sensitivity.

Clinical utility demonstrated; testing can direct treatment (see chunk 23 and policy statement in chunk 1).

Female relative of a patient with a known DMD-associated dystrophinopathy for targeted testing for a known familial variant to determine carrier status.

Targeted familial variant testing in female relative: Female relative of a patient with a known DMD-associated dystrophinopathy who receives targeted testing for a known familial DMD variant to determine carrier status; results guide cardiac surveillance and reproductive decision making.

Published data for clinical validity are limited but expected to be high; chain of evidence supports clinical utility (see chunk 23).

Asymptomatic male offspring or asymptomatic male sibling of a patient with a DMD familial variant for targeted testing to determine DMD status.

Targeted testing in asymptomatic male relatives: Asymptomatic male offspring or asymptomatic male sibling of a patient with a known familial DMD variant who receive targeted testing for that known familial variant to determine DMD status and the need for increased medical and cardiac surveillance.

Clinical utility inferred from surveillance implications; definition of at-risk AMB provided in Policy Guidelines (chunk 2 and chunk 24).

BMD has later onset and milder skeletal muscle involvement compared with DMD, consistent with the wider CK range

Presentation noteCK elevation in BMD can accompany progressive symmetric muscle weakness and calf hypertrophy

Identification of a code in the coding section does not denote coverage.
Coverage is determined by the member's benefit and the medical necessity of the service.
Prior authorization may be required per the member's benefit.
Not all covered services are eligible for separate reimbursement.

Documentation Required

Clinical and Familial Documentation Requirements

Documentation submitted with the request should support clinical signs and symptoms consistent with a dystrophinopathy and include relevant family history and relationship to any known familial DMD variant. For relatives, indicate whether testing is targeted for a known familial variant or is diagnostic for a symptomatic individual. Clinical notes should include examination findings (e.g., gait disturbance, Gower sign, pseudo-hypertrophy), laboratory data (e.g., markedly elevated CK), and prior genetic test results, if any.

Document clinical signs and symptoms consistent with dystrophinopathy (abnormal gait, difficulty rising, frequent falls, Gower sign, calf pseudohypertrophy).
Provide serum creatine kinase results and relevant laboratory data.
Specify family history and relationship to affected individual and whether testing is targeted to a known familial variant.
Include prior genetic testing results (deletion/duplication testing, sequencing) and, if deletion/duplication testing was negative, indicate whether sequencing or muscle biopsy is being considered.

Note

Linkage to Variant-Targeted Therapies

Some therapies are variant-specific and require a confirmed molecular diagnosis before initiation. Examples include exon-skipping therapies (eteplirsen/Exondys 51, golodirsen/Vyondys 53, viltolarsen/Viltepso, casimersen/Amondys 45) and gene therapy (delandistrogene moxeparvovec-rokl/Elevidys). When testing is being performed to determine eligibility for variant-targeted treatment, the documentation should clearly state the intended therapy and confirm that identified variants are those amenable to the specific treatment.

State if testing is to confirm eligibility for a specific exon-skipping therapy or gene therapy.
Ensure the reported variant is described and matched to the therapy-specific indication (e.g., exon 51, 53, or 45 skipping eligibility).
Therapy initiation decisions require a confirmed pathogenic variant that is amenable to the targeted treatment.

AFB heterozygotes are at increased risk for cardiomyopathy and require routine cardiac surveillance

Use in coverage criteriaThis at-risk definition is used to determine who may be eligible for targeted familial variant testing for carrier status

inv-21: At-risk offspring assigned male at birth (AMB)

Definition of at-risk AMB offspringAn at-risk offspring assigned male at birth (AMB) is an asymptomatic AMB child of an AFB carrier or an asymptomatic AMB sibling of an individual with a DMD-associated dystrophinopathy

Purpose of testingTargeted testing in at-risk AMB offspring is intended to determine DMD status to guide medical and cardiac surveillance

Coverage implicationThis definition informs eligibility for targeted familial variant testing under the policy

inv-22: Dystrophinopathies/DMD gene

Gene specificityDMD is the only gene with variants known to cause Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and DMD-associated cardiomyopathy

Molecular confirmationMolecular genetic testing identifying a pathogenic variant in the DMD gene establishes diagnosis of DMD/BMD in most patients without muscle biopsy

Variant burdenThe DMD gene has a complex variant spectrum with over 5,000 reported disease-associated variants and a high de novo variant rate